Furthermore, analysis of the TCGA database revealed that IGF2BP2 expression was significantly higher in stage III/IV HCC samples than in stage I/II, and its expression increased progressively with tumor grade (Fig. 6J, K). The gene discussed is IGF2BP2; the disease is hepatocellular carcinoma.